Impact of prior flavivirus immunity on Zika virus infection in rhesus macaques

PLoS Pathogens

Volumn 13, Issue 8, 2017, Pages

  McCracken, Michael K ^a   Gromowski, Gregory D ^a   Friberg, Heather L ^a   Lin, Xiaoxu ^a   Abbink, Peter ^b   De La Barrera, Rafael ^a   Eckles, Kenneth H ^a   Garver, Lindsey S ^a   Boyd, Michael ^b   Jetton, David ^b   Barouch, Dan H ^b   Wise, Matthew C ^a   Lewis, Bridget S ^a   Currier, Jeffrey R ^a   Modjarrad, Kayvon ^a,c   Milazzo, Mark ^a,c   Liu, Michelle ^a,c   Mullins, Anna B ^a   Putnak, J Robert ^a   Michael, Nelson L ^a   Jarman, Richard G ^a   Thomas, Stephen J ^a   more..

^a WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c HENRY M JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CALCIUM; CARBON DIOXIDE; CHLORIDE; CHOLESTEROL; CREATINE KINASE; CREATININE; GAMMA GLUTAMYLTRANSFERASE; GLUCOSE; LACTATE DEHYDROGENASE; NEUTRALIZING ANTIBODY; NITROGEN; PHOSPHORUS; POTASSIUM; PROTEIN; SODIUM; TRIACYLGLYCEROL; UREA; VIRUS ANTIBODY;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY TITER; ARTICLE; BLOOD CELL COUNT; CEREBROSPINAL FLUID ANALYSIS; CLINICAL CHEMISTRY; CONTROLLED STUDY; DENGUE VIRUS 2; DENGUE VIRUS 4; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLAVIVIRUS; FLOW CYTOMETRY; HEMATOLOGY; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PLAQUE REDUCTION NEUTRALIZATION TEST; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RHESUS MONKEY; VIRUS IMMUNITY; VIRUS LOAD; VIRUS NEUTRALIZATION; YELLOW FEVER VIRUS; ZIKA FEVER; ANIMAL; CROSS REACTION; FLAVIVIRUS INFECTION; IMMUNOLOGY; PATHOLOGY; POLYMERASE CHAIN REACTION; ZIKA VIRUS;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CROSS REACTIONS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLAVIVIRUS; FLAVIVIRUS INFECTIONS; MACACA MULATTA; POLYMERASE CHAIN REACTION; ZIKA VIRUS; ZIKA VIRUS INFECTION;

EID: 85028624678     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1006487     Document Type: Article

References (49)

1. Dick GW, Kitchen SF, Haddow AJ, Zika virus. I. Isolations and serological specificity. Transactions of the Royal Society of Tropical Medicine and Hygiene. 1952;46(5):509–20. 12995440.
2. Macnamara FN, Zika virus: a report on three cases of human infection during an epidemic of jaundice in Nigeria. Transactions of the Royal Society of Tropical Medicine and Hygiene. 1954;48(2):139–45. 13157159.
3. Centers for Disease Control and Prevention. Zika virus transmission and risk 2016 [updated July 25, 2016August 1, 2016]. http://www.cdc.gov/zika/transmission/index.html.
4. Messina JP, Brady OJ, Scott TW, Zou C, Pigott DM, Duda KA, et al. Global spread of dengue virus types: mapping the 70 year history. Trends in microbiology. 2014;22(3):138–46. doi: 10.1016/j.tim.2013.12.011 24468533.
5. Centers for Disease Control and Prevention. Geographic Distribution of Japanese Encephalitis Virus 2016 [updated August 5, 2015August 1, 2016]. http://www.cdc.gov/japaneseencephalitis/maps/index.html.
6. Centers for Disease Control and Prevention. Areas with Risk of Yellow Fever Virus Transmission in South America 2016 [updated July 12, 2016August 1, 2016]. https://www.cdc.gov/yellowfever/maps/south_america.html.
7. World Health Organization. Zika virus, Microcephaly and Guillain-Barré syndrome 2016 [updated December 29, 2016]. http://apps.who.int/iris/bitstream/10665/252672/1/zikasitrep29Dec16-eng.pdf.
8. Centers for Disease Control and Prevention. Florida investigation links four recent Zika cases to local mosquito-borne virus transmission 2016 [updated July 29, 2016July 29, 2016]. http://www.cdc.gov/media/releases/2016/p0729-florida-zika-cases.html.
9. Pacheco O, Beltran M, Nelson CA, Valencia D, Tolosa N, Farr SL, et al. Zika Virus Disease in Colombia—Preliminary Report. The New England journal of medicine. 2016. doi: 10.1056/NEJMoa1604037 27305043.
10. Johansson MA, Mier-y-Teran-Romero L, Reefhuis J, Gilboa SM, Hills SL, Zika and the Risk of Microcephaly. The New England journal of medicine. 2016;375(1):1–4. doi: 10.1056/NEJMp1605367 27222919.
11. Cao-Lormeau VM, Blake A, Mons S, Lastere S, Roche C, Vanhomwegen J, et al. Guillain-Barre Syndrome outbreak associated with Zika virus infection in French Polynesia: a case-control study. Lancet. 2016;387(10027):1531–9. doi: 10.1016/S0140-6736(16)00562-6 26948433.
12. Larocca RA, Abbink P, Peron JP, Zanotto PM, Iampietro MJ, Badamchi-Zadeh A, et al. Vaccine protection against Zika virus from Brazil. Nature. 2016;536(7617):474–8. doi: 10.1038/nature18952 27355570.
13. Abbink P, Larocca RA, De La Barrera RA, Bricault CA, Moseley ET, Boyd M, et al. Protective efficacy of multiple vaccine platforms against Zika virus challenge in rhesus monkeys. Science. 2016;353(6304):1129–32. doi: 10.1126/science.aah6157 27492477.
14. Dowd KA, Ko SY, Morabito KM, Yang ES, Pelc RS, DeMaso CR, et al. Rapid development of a DNA vaccine for Zika virus. Science. 2016;354(6309):237–40. doi: 10.1126/science.aai9137 27708058.
15. Muthumani K, Griffin BD, Agarwal S, Kudchodkar SB, Reuschel EL, Choi H, et al. In vivo protection against ZIKV infection and pathogenesis through passive antibody transfer and active immunisation with a prMEnv DNA vaccine. Npj Vaccines. 2016;1:16021. http://www.nature.com/articles/npjvaccines201621#supplementary-information.
16. Libraty DH, Young PR, Pickering D, Endy TP, Kalayanarooj S, Green S, et al. High circulating levels of the dengue virus nonstructural protein NS1 early in dengue illness correlate with the development of dengue hemorrhagic fever. The Journal of infectious diseases. 2002;186(8):1165–8. doi: 10.1086/343813 12355369.
17. Wang WK, Chao DY, Kao CL, Wu HC, Liu YC, Li CM, et al. High levels of plasma dengue viral load during defervescence in patients with dengue hemorrhagic fever: implications for pathogenesis. Virology. 2003;305(2):330–8. 12573578.
18. Vaughn DW, Green S, Kalayanarooj S, Innis BL, Nimmannitya S, Suntayakorn S, et al. Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity. The Journal of infectious diseases. 2000;181(1):2–9. doi: 10.1086/315215 10608744.
19. Murphy BR, Whitehead SS, Immune response to dengue virus and prospects for a vaccine. Annual review of immunology. 2011;29:587–619. doi: 10.1146/annurev-immunol-031210-101315 21219187.
20. Libraty DH, Endy TP, Houng HS, Green S, Kalayanarooj S, Suntayakorn S, et al. Differing influences of virus burden and immune activation on disease severity in secondary dengue-3 virus infections. The Journal of infectious diseases. 2002;185(9):1213–21. doi: 10.1086/340365 12001037.
21. Rothman AL, Immunity to dengue virus: a tale of original antigenic sin and tropical cytokine storms. Nature reviews Immunology. 2011;11(8):532–43. doi: 10.1038/nri3014 21760609.
22. Anderson KB, Gibbons RV, Thomas SJ, Rothman AL, Nisalak A, Berkelman RL, et al. Preexisting Japanese encephalitis virus neutralizing antibodies and increased symptomatic dengue illness in a school-based cohort in Thailand. PLoS neglected tropical diseases. 2011;5(10):e1311. doi: 10.1371/journal.pntd.0001311 21991398.
23. Hoke CH, Nisalak A, Sangawhipa N, Jatanasen S, Laorakapongse T, Innis BL, et al. Protection against Japanese encephalitis by inactivated vaccines. The New England journal of medicine. 1988;319(10):608–14. doi: 10.1056/NEJM198809083191004 2842677.
24. Stettler K, Beltramello M, Espinosa DA, Graham V, Cassotta A, Bianchi S, et al. Specificity, cross-reactivity, and function of antibodies elicited by Zika virus infection. Science. 2016;353(6301):823–6. doi: 10.1126/science.aaf8505 27417494.
25. Priyamvada L, Quicke KM, Hudson WH, Onlamoon N, Sewatanon J, Edupuganti S, et al. Human antibody responses after dengue virus infection are highly cross-reactive to Zika virus. Proceedings of the National Academy of Sciences of the United States of America. 2016;113(28):7852–7. doi: 10.1073/pnas.1607931113 27354515.
26. Dejnirattisai W, Supasa P, Wongwiwat W, Rouvinski A, Barba-Spaeth G, Duangchinda T, et al. Dengue virus sero-cross-reactivity drives antibody-dependent enhancement of infection with zika virus. Nature immunology. 2016;17(9):1102–8. doi: 10.1038/ni.3515 27339099.
27. Barba-Spaeth G, Dejnirattisai W, Rouvinski A, Vaney MC, Medits I, Sharma A, et al. Structural basis of potent Zika-dengue virus antibody cross-neutralization. Nature. 2016;536(7614):48–53. doi: 10.1038/nature18938 27338953.
28. Fagbami AH, Halstead SB, Marchette NJ, Larsen K, Cross-infection enhancement among African flaviviruses by immune mouse ascitic fluids. Cytobios. 1987;49(196):49–55. 3028713.
29. Swaminathan S, Schlaberg R, Lewis J, Hanson KE, Couturier MR, Fatal Zika Virus Infection with Secondary Nonsexual Transmission. The New England journal of medicine. 2016;375(19):1907–9. doi: 10.1056/NEJMc1610613 27681699.
30. Mongkolsapaya J, Dejnirattisai W, Xu XN, Vasanawathana S, Tangthawornchaikul N, Chairunsri A, et al. Original antigenic sin and apoptosis in the pathogenesis of dengue hemorrhagic fever. Nature medicine. 2003;9(7):921–7. doi: 10.1038/nm887 12808447.
31. Friberg H, Bashyam H, Toyosaki-Maeda T, Potts JA, Greenough T, Kalayanarooj S, et al. Cross-reactivity and expansion of dengue-specific T cells during acute primary and secondary infections in humans. Scientific reports. 2011;1:51. doi: 10.1038/srep00051 22355570.
32. Dung NT, Duyen HT, Thuy NT, Ngoc TV, Chau NV, Hien TT, et al. Timing of CD8+ T cell responses in relation to commencement of capillary leakage in children with dengue. Journal of immunology. 2010;184(12):7281–7. doi: 10.4049/jimmunol.0903262 20483770.
33. Duangchinda T, Dejnirattisai W, Vasanawathana S, Limpitikul W, Tangthawornchaikul N, Malasit P, et al. Immunodominant T-cell responses to dengue virus NS3 are associated with DHF. Proceedings of the National Academy of Sciences of the United States of America. 2010;107(39):16922–7. doi: 10.1073/pnas.1010867107 20837518.
34. Mongkolsapaya J, Duangchinda T, Dejnirattisai W, Vasanawathana S, Avirutnan P, Jairungsri A, et al. T cell responses in dengue hemorrhagic fever: are cross-reactive T cells suboptimal?Journal of immunology. 2006;176(6):3821–9. 16517753.
35. Simmons CP, Dong T, Chau NV, Dung NT, Chau TN, Thao le TT, et al. Early T-cell responses to dengue virus epitopes in Vietnamese adults with secondary dengue virus infections. Journal of virology. 2005;79(9):5665–75. doi: 10.1128/JVI.79.9.5665-5675.2005 15827181.
36. Clapham HE, Rodriguez-Barraquer I, Azman AS, Althouse BM, Salje H, Gibbons RV, et al. Dengue Virus (DENV) Neutralizing Antibody Kinetics in Children After Symptomatic Primary and Postprimary DENV Infection. The Journal of infectious diseases. 2016;213(9):1428–35. doi: 10.1093/infdis/jiv759 26704615.
37. Sabin AB, Research on dengue during World War II. The American journal of tropical medicine and hygiene. 1952;1(1):30–50. 14903434.
38. Snow GE, Haaland B, Ooi EE, Gubler DJ, Review article: Research on dengue during World War II revisited. The American journal of tropical medicine and hygiene. 2014;91(6):1203–17. doi: 10.4269/ajtmh.14-0132 25311700.
39. Libraty DH, Acosta LP, Tallo V, Segubre-Mercado E, Bautista A, Potts JA, et al. A prospective nested case-control study of Dengue in infants: rethinking and refining the antibody-dependent enhancement dengue hemorrhagic fever model. PLoS medicine. 2009;6(10):e1000171. doi: 10.1371/journal.pmed.1000171 19859541.
40. Austin SK, Dowd KA, B cell response and mechanisms of antibody protection to West Nile virus. Viruses. 2014;6(3):1015–36. doi: 10.3390/v6031015 24594676.
41. Halstead SB, Shotwell H, Casals J, Studies on the pathogenesis of dengue infection in monkeys. II. Clinical laboratory responses to heterologous infection. The Journal of infectious diseases. 1973;128(1):15–22. 4198024.
42. Halstead SB, In vivo enhancement of dengue virus infection in rhesus monkeys by passively transferred antibody. The Journal of infectious diseases. 1979;140(4):527–33. 117061.
43. Goncalvez AP, Engle RE, St Claire M, Purcell RH, Lai CJ, Monoclonal antibody-mediated enhancement of dengue virus infection in vitro and in vivo and strategies for prevention. Proceedings of the National Academy of Sciences of the United States of America. 2007;104(22):9422–7. doi: 10.1073/pnas.0703498104 17517625.
44. Dudley DM, Aliota MT, Mohr EL, Weiler AM, Lehrer-Brey G, Weisgrau KL, et al. A rhesus macaque model of Asian-lineage Zika virus infection. Nature communications. 2016;7:12204. doi: 10.1038/ncomms12204 27352279.
45. Simoni MK, Jurado KA, Abrahams VM, Fikrig E, Guller S, Zika virus infection of Hofbauer cells. American journal of reproductive immunology. 2017;77(2). doi: 10.1111/aji.12613 27966815.
46. Mor G, Cardenas I, The immune system in pregnancy: a unique complexity. American journal of reproductive immunology. 2010;63(6):425–33. doi: 10.1111/j.1600-0897.2010.00836.x 20367629.
47. Johnson AJ, Martin DA, Karabatsos N, Roehrig JT, Detection of anti-arboviral immunoglobulin G by using a monoclonal antibody-based capture enzyme-linked immunosorbent assay. Journal of clinical microbiology. 2000;38(5):1827–31. 10790108.
48. Thomas SJ, Eckels KH, Carletti I, De La Barrera R, Dessy F, Fernandez S, et al. A phase II, randomized, safety and immunogenicity study of a re-derived, live-attenuated dengue virus vaccine in healthy adults. The American journal of tropical medicine and hygiene. 2013;88(1):73–88. doi: 10.4269/ajtmh.2012.12-0361 23208878.
49. Kraus AA, Messer W, Haymore LB, de Silva AM, Comparison of plaque- and flow cytometry-based methods for measuring dengue virus neutralization. Journal of clinical microbiology. 2007;45(11):3777–80. doi: 10.1128/JCM.00827-07 17804661.